-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Zhendong Pharmaceutical issued an announcement that its director and president Ma Shifeng has submitted a written application for resignation.
Due to personal reasons, he has applied for resignation from the positions of director, president, member of the Board of Directors' Compensation and Appraisal Committee, and member of the Audit Committee of the Board of Directors
.
After resigning the above-mentioned position, Ma Shifeng no longer holds any position in the company
.
It is understood that Mr.
Ma Shifeng's original term of office will expire on the expiry date of the fifth board of directors
.
Although it has resigned early, Zhendong Pharmaceutical said that it will not cause the company's board of directors to be less than the quorum, will not affect the normal operation of the company's board of directors, and will not adversely affect the company's daily operations
.
In addition to the aforementioned changes in the executive management of Zhendong Pharmaceutical, according to incomplete statistics, over a hundred executives in the pharmaceutical industry have resigned since the beginning of this year
.
In the first half of November alone, more than 14 senior executives of domestic and foreign pharmaceutical companies have resigned, many of them including the chairman, general manager and other executives
.
It is worth noting that in the past week, there have been changes in the senior management of many pharmaceutical companies such as Yingtai Biological, Kanghong Pharmaceutical, and Liaoning Chengda
.
On November 18, Yingtai Biotechnology issued an announcement stating that it received a resignation report from director Cai Aiguo on the 16th.
He resigned as a director of the company's board of directors due to physical reasons and continued to serve as a director of the company's subsidiary after resignation
.
At the same time, the board of directors held on November 16 approved and nominated Zhou Shuguang as a director of the company
.
On November 16, three consecutive companies issued announcements that some senior executives had resigned
.
Among them, Chongqing Laimei Pharmaceutical issued an announcement stating that the company's supervisor and securities affairs representative Chen Feng applied to resign from the position of non-employee representative supervisor and securities affairs representative of the company's fifth board of supervisors due to personal reasons
.
After resignation, he will no longer hold any position in the company
.
Kanghong Pharmaceutical issued an announcement stating that ChenSU applied to resign from the company's directorship due to personal reasons, and at the same time resigned from the position of vice president.
After resignation, he will no longer hold any position in the company
.
In addition, Liaoning Chengda University also issued an announcement stating that Mr.
Xie Deren, due to personal reasons, has applied for resignation as an independent director of the company's tenth board of directors, chairman of the audit committee, member of the nomination committee, and member of the remuneration and appraisal committee.
.
The analysis believes that the frequent wave of resignations by pharmaceutical companies is mainly due to the continuous advancement of relevant policies in the domestic pharmaceutical field, which makes pharmaceutical companies have to start adjusting their business forms or directly transform their corporate structures; in this process, some senior executives have been affected Can only choose to leave the job actively or passively
.
In fact, in addition to local pharmaceutical companies, multinational pharmaceutical companies are accelerating their choice to adjust their corporate structure under the influence of the pharmaceutical environment, while their personnel changes are becoming more and more frequent
.
For example, Du Haochen, vice president of AstraZeneca China and head of the county business department, also decided to leave the company due to personal reasons.
His term of office will officially end on November 17, 2021
.
What is worth mentioning is that it has been revealed that he will join BeiGene as the head of the broad market after leaving his post
.
The industry believes that as domestic and foreign pharmaceutical companies continue to adjust their corporate structure and strategic planning, or will further intensify the flow of talents and competition between companies, the "grabbing battle" of pharmaceutical companies will become more and more intense
.
Due to personal reasons, he has applied for resignation from the positions of director, president, member of the Board of Directors' Compensation and Appraisal Committee, and member of the Audit Committee of the Board of Directors
.
After resigning the above-mentioned position, Ma Shifeng no longer holds any position in the company
.
It is understood that Mr.
Ma Shifeng's original term of office will expire on the expiry date of the fifth board of directors
.
Although it has resigned early, Zhendong Pharmaceutical said that it will not cause the company's board of directors to be less than the quorum, will not affect the normal operation of the company's board of directors, and will not adversely affect the company's daily operations
.
In addition to the aforementioned changes in the executive management of Zhendong Pharmaceutical, according to incomplete statistics, over a hundred executives in the pharmaceutical industry have resigned since the beginning of this year
.
In the first half of November alone, more than 14 senior executives of domestic and foreign pharmaceutical companies have resigned, many of them including the chairman, general manager and other executives
.
It is worth noting that in the past week, there have been changes in the senior management of many pharmaceutical companies such as Yingtai Biological, Kanghong Pharmaceutical, and Liaoning Chengda
.
On November 18, Yingtai Biotechnology issued an announcement stating that it received a resignation report from director Cai Aiguo on the 16th.
He resigned as a director of the company's board of directors due to physical reasons and continued to serve as a director of the company's subsidiary after resignation
.
At the same time, the board of directors held on November 16 approved and nominated Zhou Shuguang as a director of the company
.
On November 16, three consecutive companies issued announcements that some senior executives had resigned
.
Among them, Chongqing Laimei Pharmaceutical issued an announcement stating that the company's supervisor and securities affairs representative Chen Feng applied to resign from the position of non-employee representative supervisor and securities affairs representative of the company's fifth board of supervisors due to personal reasons
.
After resignation, he will no longer hold any position in the company
.
Kanghong Pharmaceutical issued an announcement stating that ChenSU applied to resign from the company's directorship due to personal reasons, and at the same time resigned from the position of vice president.
After resignation, he will no longer hold any position in the company
.
In addition, Liaoning Chengda University also issued an announcement stating that Mr.
Xie Deren, due to personal reasons, has applied for resignation as an independent director of the company's tenth board of directors, chairman of the audit committee, member of the nomination committee, and member of the remuneration and appraisal committee.
.
The analysis believes that the frequent wave of resignations by pharmaceutical companies is mainly due to the continuous advancement of relevant policies in the domestic pharmaceutical field, which makes pharmaceutical companies have to start adjusting their business forms or directly transform their corporate structures; in this process, some senior executives have been affected Can only choose to leave the job actively or passively
.
In fact, in addition to local pharmaceutical companies, multinational pharmaceutical companies are accelerating their choice to adjust their corporate structure under the influence of the pharmaceutical environment, while their personnel changes are becoming more and more frequent
.
For example, Du Haochen, vice president of AstraZeneca China and head of the county business department, also decided to leave the company due to personal reasons.
His term of office will officially end on November 17, 2021
.
What is worth mentioning is that it has been revealed that he will join BeiGene as the head of the broad market after leaving his post
.
The industry believes that as domestic and foreign pharmaceutical companies continue to adjust their corporate structure and strategic planning, or will further intensify the flow of talents and competition between companies, the "grabbing battle" of pharmaceutical companies will become more and more intense
.
